Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) have been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 […]
Tekla Capital Management LLC lifted its holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 126.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,452 shares of the company’s stock after buying an additional 29,836 shares during the period. […]
Castleark Management LLC grew its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 121.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,936 shares of the company’s stock after purchasing an additional 13,690 shares during the quarter. Castleark Management LLC […]
Hamilton Lane Advisors LLC reduced its stake in Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) by 17.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,090 shares of the company’s stock after selling 13,196 shares during the period. Karuna Therapeutics accounts […]
Karuna Therapeutics (NASDAQ:KRTX – Get Rating) had its target price increased by Mizuho from $270.00 to $274.00 in a research note released on Monday morning, The Fly reports. KRTX has been the topic of several other reports. Wells Fargo & Company lowered their price objective on Karuna Therapeutics from $262.00 to $257.00 and set an […]